ArticleCell biochemistry and biophysics2025
Recombinant α-Toxin BmK-M9 Inhibits Breast Cancer Progression by Regulating β-Catenin In Vivo.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Screening bioactive compounds from natural sources, including animals and plants, is a valuable strategy for identifying novel anti-tumor agents. α-Toxin BmK-M9, a key component of scorpion venom, has received limited attention regarding its potential anti-cancer effects and underlying mechanisms in breast cancer. This study investigates the effects and mechanisms of BmK-M9 in breast cancer using in vitro experiments and a nude mouse model. mRNA sequencing was performed to identify affected signaling pathways, while Western blotting and immunohistochemistry were utilized to analyze the Wnt/β-catenin signaling pathway. The results demonstrated that BmK-M9 significantly inhibited breast cancer cell invasion and migration in vitro and suppressed tumor growth in vivo. Transcriptomic analysis revealed that BmK-M9 influenced cellular processes related to proliferation, apoptosis, motility, and metabolism. Furthermore, BmK-M9 markedly downregulated β-catenin expression in the Wnt/β-catenin pathway. These findings suggest that BmK-M9 exerts anti-tumor effects in breast cancer by modulating Wnt/β-catenin signaling, highlighting its potential as a promising therapeutic candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.